Search: onr:"swepub:oai:DiVA.org:uu-181876" >
No evidence for add...
No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds
-
van Assema, Danielle M. E. (author)
-
Goos, Jeroen D. C. (author)
-
van der Flier, Wiesje M. (author)
-
show more...
-
- Lubberink, Mark (author)
- Uppsala universitet,Enheten för nuklearmedicin och PET
-
Boellaard, Ronald (author)
-
Windhorst, Albert D. (author)
-
Scheltens, Philip (author)
-
Lammertsma, Adriaan A. (author)
-
van Berckel, Bart N. M. (author)
-
show less...
-
(creator_code:org_t)
- 2012-05-16
- 2012
- English.
-
In: Journal of Cerebral Blood Flow and Metabolism. - : SAGE Publications. - 0271-678X .- 1559-7016. ; 32:8, s. 1468-1471
- Related links:
-
https://journals.sag...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Decreased blood-brain barrier P-glycoprotein (Pgp) function has been shown in Alzheimer's disease (AD) patients using positron emission tomography (PET) with the radiotracer (R)-[C-11] verapamil. Decreased Pgp function has also been hypothesized to promote cerebral amyloid angiopathy (CAA) development. Here, we used PET and (R)-[C-11] verapamil to assess Pgp function in eighteen AD patients, of which six had microbleeds (MBs), presumably reflecting underlying CAA. No differences were found in binding potential and nonspecific volume of distribution of (R)-[C-11] verapamil between patient groups. These results provide no evidence for additional Pgp dysfunction in AD patients with MBs.
Keyword
- Alzheimer's disease
- blood-brain barrier
- cerebral amyloid angiopathy
- P-glycoprotein
- positron emission tomography
- (R)-[C-11]verapamil
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database